Header Logo

Connection

RENE GONZALEZ to Melanoma

Back to Details
This is a "connection" page, showing publications RENE GONZALEZ has written about Melanoma.
RENE GONZALEZ
Connection Strength
8.755
Melanoma
  1. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704.
    View in: PubMed
    Score: 0.273
  2. Novel therapies in melanoma. Immunotherapy. 2011 Dec; 3(12):1461-9.
    View in: PubMed
    Score: 0.225
  3. Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy. 2011 Jan; 3(1):17-21.
    View in: PubMed
    Score: 0.211
  4. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010 Jun; 20(3):218-26.
    View in: PubMed
    Score: 0.202
  5. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 Jan 01; 116(1):155-63.
    View in: PubMed
    Score: 0.197
  6. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
    View in: PubMed
    Score: 0.194
  7. Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature. Int J Dermatol. 2009 Apr; 48(4):426-30.
    View in: PubMed
    Score: 0.187
  8. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs. 2008 Feb; 26(1):89-94.
    View in: PubMed
    Score: 0.168
  9. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 Oct; 14(10):2854-60.
    View in: PubMed
    Score: 0.165
  10. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006 Dec; 16(6):521-6.
    View in: PubMed
    Score: 0.159
  11. Metastatic melanoma in the breast: a report of 27 cases. J Surg Oncol. 2006 Aug 01; 94(2):101-4.
    View in: PubMed
    Score: 0.155
  12. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol. 2006 Jul 01; 24(19):3157-63.
    View in: PubMed
    Score: 0.154
  13. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan; 24(1):89-94.
    View in: PubMed
    Score: 0.149
  14. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF. Cancer Invest. 2005; 23(4):303-8.
    View in: PubMed
    Score: 0.139
  15. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. 2024 Nov 15; 155(10):1792-1807.
    View in: PubMed
    Score: 0.135
  16. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
    View in: PubMed
    Score: 0.123
  17. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma. Expert Opin Biol Ther. 2003 Apr; 3(2):377-84.
    View in: PubMed
    Score: 0.123
  18. A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. Invest New Drugs. 2002 Aug; 20(3):357-62.
    View in: PubMed
    Score: 0.118
  19. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer. 2002 Jan 15; 94(2):470-6.
    View in: PubMed
    Score: 0.113
  20. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
    View in: PubMed
    Score: 0.112
  21. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022 01 10; 40(2):127-137.
    View in: PubMed
    Score: 0.112
  22. Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res. 2021 02 01; 31(1):67-75.
    View in: PubMed
    Score: 0.106
  23. Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. Mol Cancer Res. 2021 02; 19(2):346-357.
    View in: PubMed
    Score: 0.104
  24. Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 10 16; 11(1):5259.
    View in: PubMed
    Score: 0.104
  25. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683.
    View in: PubMed
    Score: 0.099
  26. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
    View in: PubMed
    Score: 0.097
  27. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. J Surg Oncol. 2019 Dec; 120(7):1276-1283.
    View in: PubMed
    Score: 0.097
  28. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
    View in: PubMed
    Score: 0.097
  29. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546.
    View in: PubMed
    Score: 0.097
  30. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935.
    View in: PubMed
    Score: 0.094
  31. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019 04 10; 37(11):867-875.
    View in: PubMed
    Score: 0.093
  32. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49.
    View in: PubMed
    Score: 0.093
  33. 68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging. Sci Transl Med. 2018 11 07; 10(466).
    View in: PubMed
    Score: 0.091
  34. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1480-1492.
    View in: PubMed
    Score: 0.090
  35. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018 Oct; 63:282-291.
    View in: PubMed
    Score: 0.089
  36. Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. J Neurooncol. 2018 Oct; 140(1):55-62.
    View in: PubMed
    Score: 0.088
  37. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590.
    View in: PubMed
    Score: 0.085
  38. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45.
    View in: PubMed
    Score: 0.085
  39. ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 01; 17(1):222-231.
    View in: PubMed
    Score: 0.084
  40. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2018 03 01; 36(7):667-673.
    View in: PubMed
    Score: 0.084
  41. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 10 05; 377(14):1345-1356.
    View in: PubMed
    Score: 0.084
  42. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017 11 09; 377(19):1824-1835.
    View in: PubMed
    Score: 0.084
  43. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 Dec 01; 35(34):3807-3814.
    View in: PubMed
    Score: 0.084
  44. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017 09; 82:80-91.
    View in: PubMed
    Score: 0.083
  45. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544.
    View in: PubMed
    Score: 0.079
  46. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 08; 14(8):945-58.
    View in: PubMed
    Score: 0.078
  47. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Apr; 14(4):450-73.
    View in: PubMed
    Score: 0.076
  48. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun. 2016 Feb; 37(2):122-8.
    View in: PubMed
    Score: 0.075
  49. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8.
    View in: PubMed
    Score: 0.075
  50. Association of sentinel lymph node diameter with melanoma metastasis. Am J Surg. 2016 Aug; 212(2):315-20.
    View in: PubMed
    Score: 0.075
  51. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
    View in: PubMed
    Score: 0.072
  52. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015 Jul 02; 373(1):23-34.
    View in: PubMed
    Score: 0.072
  53. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015 May; 72(5):780-5.e3.
    View in: PubMed
    Score: 0.070
  54. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clin Cancer Res. 2015 May 15; 21(10):2289-96.
    View in: PubMed
    Score: 0.070
  55. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015 Jan 01; 21(1):175-83.
    View in: PubMed
    Score: 0.070
  56. A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma. Cancer Med. 2015 May; 4(5):643-50.
    View in: PubMed
    Score: 0.069
  57. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
    View in: PubMed
    Score: 0.069
  58. A review of novel therapies for melanoma. Am J Clin Dermatol. 2014 Aug; 15(4):323-37.
    View in: PubMed
    Score: 0.068
  59. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
    View in: PubMed
    Score: 0.067
  60. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014 May; 12(5):621-9.
    View in: PubMed
    Score: 0.066
  61. Anti-CTLA4 antibody therapy related complications on FDG PET/CT. Clin Nucl Med. 2014 Jan; 39(1):e93-6.
    View in: PubMed
    Score: 0.065
  62. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014 Jan-Feb; 20(1):18-24.
    View in: PubMed
    Score: 0.065
  63. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):197-202.
    View in: PubMed
    Score: 0.064
  64. New targeted therapies in melanoma. Cancer Control. 2013 Oct; 20(4):282-8.
    View in: PubMed
    Score: 0.064
  65. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
    View in: PubMed
    Score: 0.063
  66. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
    View in: PubMed
    Score: 0.062
  67. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013 May; 148(5):456-61.
    View in: PubMed
    Score: 0.062
  68. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
    View in: PubMed
    Score: 0.062
  69. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9.
    View in: PubMed
    Score: 0.060
  70. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236.
    View in: PubMed
    Score: 0.060
  71. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703.
    View in: PubMed
    Score: 0.059
  72. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9.
    View in: PubMed
    Score: 0.059
  73. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy. 2012 Jul; 4(7):679-86.
    View in: PubMed
    Score: 0.058
  74. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
    View in: PubMed
    Score: 0.058
  75. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14.
    View in: PubMed
    Score: 0.057
  76. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 02; 364(22):2119-27.
    View in: PubMed
    Score: 0.054
  77. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34.
    View in: PubMed
    Score: 0.054
  78. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
    View in: PubMed
    Score: 0.054
  79. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 2010 Aug 01; 116(15):3683-91.
    View in: PubMed
    Score: 0.051
  80. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19; 363(8):711-23.
    View in: PubMed
    Score: 0.051
  81. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010 Apr 15; 16(8):2402-8.
    View in: PubMed
    Score: 0.050
  82. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
    View in: PubMed
    Score: 0.050
  83. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol. 2009 Dec 20; 27(36):6207-12.
    View in: PubMed
    Score: 0.049
  84. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71.
    View in: PubMed
    Score: 0.049
  85. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol. 2009 Nov 10; 27(32):5452-8.
    View in: PubMed
    Score: 0.048
  86. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30.
    View in: PubMed
    Score: 0.047
  87. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.046
  88. The absent-minded professor: an unusual complication of melanoma. Oncology (Williston Park). 2008 Dec; 22(14):1609-14.
    View in: PubMed
    Score: 0.046
  89. Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res. 2009 Jun 01; 154(1):13-20.
    View in: PubMed
    Score: 0.044
  90. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008 May 01; 26(13):2178-85.
    View in: PubMed
    Score: 0.044
  91. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006 Dec; 192(6):878-81.
    View in: PubMed
    Score: 0.040
  92. Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass. Oncology (Williston Park). 2006 Jun; 20(7):763-70.
    View in: PubMed
    Score: 0.038
  93. Lymphangiomatosis masquerading as metastatic melanoma. Am Surg. 2006 Apr; 72(4):367-70.
    View in: PubMed
    Score: 0.038
  94. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 2006 Feb 15; 12(4):1137-43.
    View in: PubMed
    Score: 0.038
  95. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005 Nov 01; 23(31):8057-64.
    View in: PubMed
    Score: 0.037
  96. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J Clin Oncol. 2005 Dec 10; 23(35):8992-9000.
    View in: PubMed
    Score: 0.037
  97. Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg. 2005 Jun; 40(6):988-92; discussion 992.
    View in: PubMed
    Score: 0.036
  98. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005 Jan; 140(1):85-9.
    View in: PubMed
    Score: 0.035
  99. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005 Jan; 40(1):232-5.
    View in: PubMed
    Score: 0.035
  100. Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of 177Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Mol Pharm. 2024 Aug 05; 21(8):4004-4011.
    View in: PubMed
    Score: 0.034
  101. A young woman with melanoma diagnosed during pregnancy. Oncology (Williston Park). 2004 Jun; 18(7):794-9.
    View in: PubMed
    Score: 0.033
  102. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.